Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
BRISBANE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference, which is taking place in Boston, MA from March 3 – 5, 2025. The management team will also participate in one-on-one investor meetings.
Fireside Chat Details:Date: Tuesday, March 4, 2025Time: 9:10 AM ESTWebcast: https://wsw.com/webcast/cowen177/vera/2022522
A replay of the event will be available for 90 days and can be accessed by visiting the 'Investor Calendar' section of the Vera Therapeutics website.
About VeraVera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera's mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera's lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger's disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. Vera also holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B cell mediated diseases. For more information, please visit www.veratx.com
For more information, please contact:
Investor Contact:Joyce AllaireLifeSci Advisors212-915-2569jallaire@lifesciadvisors.com
Media Contact:Madelin HawtinLifeSci CommunicationsMHawtin@lifescicomms.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
MongoDB Soars 14.2% After Crushing Q1 -- $1B Buyback, AI Push, and Customer Surge Spark Rally
MongoDB (NASDAQ:MDB) is off to a fast start in fiscal 2026and investors might want to take a closer look. The company reported $549 million in Q1 revenue, up 22% from last year, with its cloud product, Atlas, growing 26% and now making up 72% of total sales. Management added 2,600 new customers, marking the biggest quarterly gain in six years. The share is up 14.2% at 12.09pm today. CEO Dev Ittycheria pointed to strong traction from both enterprises and startups as AI workloads and modern app development continue to drive demand for flexible, cloud-native databases. Behind the scenes, MongoDB is becoming a cash machine. The company more than doubled non-GAAP operating income to $87.4 million and posted $105.9 million in free cash flowup 74% year-over-year. With $2.5 billion in cash and short-term investments on hand, it just authorized another $800 million in share repurchases, taking its total buyback program to $1 billion. That kind of financial firepower could give MongoDB more room to support long-term growth while returning capital to shareholders. On the AI front, MongoDB isn't just playing defense. It rolled out new retrieval modelsVoyage 3.5 and 3.5 Litethat improve accuracy and efficiency for building AI-powered apps. It also debuted its Model Context Protocol Server, which connects MongoDB to tools like GitHub Copilot and Anthropic's Claude, letting developers use natural language to interact with their data. With FY2026 revenue guidance raised up to $2.29 billion and full-year non-GAAP EPS projected to hit as high as $3.12, MongoDB could be shaping up as a quiet leader in the AI infrastructure race. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
37 minutes ago
- Business Wire
Milliman's first-ever Registered Index-Linked Annuity Experience Study shows behavior similarities with multi-year guaranteed annuity contract holders
SEATTLE--(BUSINESS WIRE)-- Milliman, Inc., a premier global consulting and actuarial firm, today announced the results of its 2025 Registered Index-Linked Annuity (RILA) Industry Experience Study. "Our recent models indicate a durational surrender trend resembling multi-year growth annuities.' -- Ben Johnson, Milliman This comprehensive study is the first of its kind for RILA and includes notable post-surrender charge period exposure. The results demonstrate that industry surrender rates remain extremely low during the surrender charge period, but rise drastically when outside of that period, with the highest increase in surrender rates observed in large-value contracts. 'Companies have speculated whether the expected shock-lapse rate for RILA would align more closely with comparable VA or FIA products,' said Ben Johnson, Milliman actuarial data scientist, Life and Annuity Predictive Analytics. 'However, our recent models indicate a third possibility: a durational surrender trend resembling multi-year growth annuities.' This latest research analyzes RILA policyholder behavior, including influencing factors such as the change in interest rates since issue, length and magnitude of the contract, methods of distribution, and tax implications. Milliman's RILA study covers surrender behavior for contracts without a withdrawal benefit (GLWB) rider. Key Findings: Distribution channels: RILA contracts are predominantly distributed through independent broker-dealers. Contracts sold through banks tend to experience higher surrender rates during the immediate period post-surrender charge, whereas those sold through large, national brokerage firms exhibit lower surrender rates compared to independent broker-dealers. Surrender charge period: Surrenders during the surrender charge period are exceptionally low, demonstrating minimal sensitivity to fluctuating interest rates. Beyond the surrender charge period, however, we observed surrender rates increase for contracts that were in force during periods of rising interest rates (for instance, since early 2022, surrender rates have trended upward for in force contracts during the post-surrender charge period). Milliman's Registered Index-Linked Annuity Experience Study introduces an advanced behavioral model that is integrated into Milliman's Recon ® platform. This model, with a 100% actual-to-expected accuracy ratio, further empowers annuity writers to conduct their own experience studies, delve into industry data, and develop tailored models. Access the Registered Index-Linked Annuity Industry Experience Study and additional experience studies here or reach out to Ben Johnson at (312) 577-2926. About Milliman Milliman leverages deep expertise, actuarial rigor, and advanced technology to develop solutions for a world at risk. We help clients in the public and private sectors navigate urgent, complex challenges—from extreme weather and market volatility to financial insecurity and rising health costs—so they can meet their business, financial, and social objectives. Our solutions encompass insurance, financial services, healthcare, life sciences, and employee benefits. Founded in 1947, Milliman is an independent firm with offices in major cities around the globe. Visit us at
Yahoo
38 minutes ago
- Yahoo
Espey Declares Regular Quarterly Dividend of $0.25 Per Share
SARATOGA SPRINGS, N.Y., June 05, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Espey Mfg. & Electronics Corp. (NYSE AMERICAN: ESP) has declared a regular quarterly dividend of $0.25 per share. The dividend will be payable on June 23, 2025 to all shareholders of record on June 16, 2025. Espey's primary business is the development, design, and production of specialized military and industrial power supplies/transformers. The Company can be found on the Internet at For further information, contact Ms. Kaitlyn O'Neil at invest@ Certain statements in this press release are "forward-looking statements" and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent the Company's current expectations or beliefs concerning future events. The matters covered by these statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. The Company wishes to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date in to access your portfolio
